Cost of new drug development is key concern for life science as focus shifts to repurposing

London, june 27, 2024 (globe newswire) -- 63% of life science companies believe the high cost of new drug development is among the emerging themes that will have the greatest negative impact on the sector in the next 3-5 years, according to global life science risk report 2024 published today by wtw (nasdaq: wtw), a leading global advisory, broking, and solutions company. this is leading to an increased focus on finding novel use cases for existing drugs, named by 66% as having a positive impact, as firms seek to launch new products and expand their international footprint.
WTW Ratings Summary
WTW Quant Ranking